The Hub for Disease-Specific Clinical Information
Advertisement
Advertisement

Recent News

INT230-6 Granted Fast Track Designation in Metastatic Triple-Negative Breast Cancer
AACR 2019: Primary Tumor Surgery for Advanced HER2-Positive Breast Cancer
AACR 2019: Predicting Breast Cancer Survival With Estrogen Byproducts
HOPA 2019: Does Receptor Expression Affect Efficacy of Talazoparib in Advanced Breast Cancer?
Is There a Link Between Age Acceleration and Breast Cancer Risk?
FDA Extends Indication of Palbociclib Combination to Men With Breast Cancer
Novel Antibody Drug-Conjugate in Metastatic Triple-Negative Breast Cancer
Study Finds Shifting Trend in Breast Cancer Risk in Asian American Women
Predicting Outcomes With Lung Immune Prognostic Index
ASCO-SITC 2019: HER2-Targeted Vaccine Plus Trastuzumab in Breast Cancer
Trastuzumab Biosimilar for HER2-Overexpressing Breast Cancer Approved by the FDA
FDA Grants Accelerated Approval to Atezolizumab Combination in Triple-Negative Breast Cancer
FDA Approves New Formulation of Trastuzumab for Subcutaneous Use in Some Breast Cancers
2019 ASCO-SITC: Neoadjuvant Chemotherapy and the Immunologic Landscape in Breast Cancer
Targeting Chemotherapy-Resistant Breast Cancer
Can Oolong Tea Inhibit Growth of Breast Cancer?
Reducing Risk for Invasive Breast Cancer With Low-Dose Tamoxifen
Comparing Breast Irradiation Regimens in Preventing Local Recurrence
Impact of Pathologic Complete Response on Breast Cancer Recurrence and Mortality
Racial Disparities in Breast Cancer Prevention: Focus on Complexity of Gathering Information
FDA Approves Trastuzumab Biosimilar for Treatment of Advanced Breast Cancer
Predictive Biomarker in Metastatic Triple-Negative Breast Cancer
Does Oxybutynin Reduce Hot Flashes in Breast Cancer Survivors?
SOLAR-1: Predicting Response to Alpelisib in PIK3CA-Mutant Breast Cancer
Can Cryoablation ‘Freeze Out’ Low-Risk Breast Cancers?
Shedding Light on Resistance to PARP Inhibitors in Patients With Breast Cancer
Conventional Whole-Breast vs. Partial-Breast Irradiation in Controlling Tumor Recurrence
Should Some Women Younger Than Age 30 Undergo Mammography?
SABCS 2018: Adjuvant Capecitabine for Early-Stage Triple-Negative Breast Cancer
SABCS 2018: Adjuvant Therapies for HER2-Positive Breast Cancer Compared in KATHERINE Trial
FDA Approves Trastuzumab Biosimilar for HER2-Overexpressing Breast Cancer
SABCS 2018: Comparing Letrozole With and Without Palbociclib in Metastatic Breast Cancer
Risk Class May Be Linked to Response to Breast Cancer Treatments
SABCS 2018: Novel Tool for Assessing Risk of Chemotherapy Toxicity in Older Patients With Breast Cancer
Rethinking Screening Mammography in Women Aged 75 and Older
SABCS 2018: Duration of Adjuvant Trastuzumab in Early Breast Cancer
SABCS 2018: When to Initiate Adjuvant Chemotherapy in Triple-Negative Breast Cancer
Shorter Course of Trastuzumab in Some HER2-Positive Early Breast Cancers
Machine-Learning Prognostic Risk Model for African American Women With Breast Cancer
Endocrine Therapy on Trial in Male Breast Cancer
HDAC Inhibitor Studied in Treatment of Advanced Breast Cancer
City of Hope Launches CAR T-Cell Trial in Patients With Breast Cancer and Brain Metastases
ESMO 2018: Zoledronic Acid and Letrozole vs. Tamoxifen in Early Breast Cancer
FDA Grants Priority Review to Atezolizumab Plus Chemotherapy in Triple-Negative Breast Cancer
ESMO 2018: Targeting the Tumor Genome in Advanced Breast Cancer
ASTRO 2018: Radiation After Surgery for Low-Risk Ductal Carcinoma in Situ
ESMO 2018: Novel Combination Therapy for Advanced Breast Cancer
Novel Regional Anesthesia Technique for Pain Management After Mastectomy
ASTRO 2018: Long-Term Effects of Once-Weekly vs. Conventional Breast Radiation
Active Monitoring for Low-Risk Ductal Carcinoma in Situ
ESMO 2018: Atezolizumab Plus Nab-Paclitaxel in Metastatic Triple-Negative Breast Cancer


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.